Professional Media briefs

Share this article:
Ian Smith, chief executive of Reed Elsevier, announced his resignation after just eight months on the job. The company tapped Erik Engstrom, CEO, as his successor. Anthony Habgood, chairman at Reed Elsevier, said Smith “had the difficult task of leading Reed Elsevier during unprecedentedly turbulent economic times.” The publisher cited declines in “pharma promotion markets, reflecting fewer drug launches and a reduction in the marketing budgets of pharmaceutical companies” in an interim management statement.

Wiley-Blackwell sold off two quarterly titles—Cochlear Implants International and Deafness & Education International —to Maney Publishing. Silvana Marciano, professional journal publisher at Wiley-Blackwell, said in a statement that the divestiture will allow the company to “concentrate our resources on our larger subject areas.” Wiley-Blackwell is a subsidiary of John Wiley & Sons.

Wolters Kluwer Health appointed Anne Dabrow Woods to the newly created position of chief nursing officer. Wolters Kluwer hopes the move will strengthen the nursing strategy at Lippincott Williams & Wilkins and Ovid, Wolters Kluwer's two health publisher subsidiaries.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?